Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial

The Lancet Infectious Diseases

Volumn 14, Issue 4, 2014, Pages 281-290

  Grinsztejn, Beatriz ^j   Hosseinipour, Mina C ^d,m   Ribaudo, Heather J ^f   Swindells, Susan ^u   Eron, Joseph ^d   Chen, Ying Q ^a   Wang, Lei ^a   Ou, San San ^a   Anderson, Maija ^a   McCauley, Marybeth ^g   Gamble, Theresa ^g   Kumarasamy, Nagalingeshwaran ⁿ   Hakim, James G ^k   Kumwenda, Johnstone ^m   Pilotto, Jose H S ^t   Godbole, Sheela V ^h   Chariyalertsak, Suwat ^c   De Melo, Marineide Gonçalves ⁱ   Mayer, Kenneth H ^p   Eshleman, Susan H ^e   Piwowar Manning, Estelle ^e   Makhema, Joseph ^o   Mills, Lisa A ^q   Panchia, Ravindre ^s   Sanne, Ian ^s   Gallant, Joel ^e   Hoffman, Irving ^d   Taha, Taha E ^b   Nielsen Saines, Karin ^r   Celentano, David ^b   Essex, Max ^f   Havlir, Diane ^l   Cohen, Myron S ^d   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g FAMILY HEALTH INTERNATIONAL   (United States)

^h NATIONAL AIDS RESEARCH INSTITUTE   (India)

ⁱ HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^j Funda??o Oswaldo Cruz   (Brazil)

^k UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF MALAWI   (Malawi)

ⁿ YR Gaitonade Center for AIDS Research and Education   (India)

^o BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^p FENWAY INSTITUTE   (United States)

^q KEMRI/CDC   (Kenya)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^t HOSPITAL GERAL DE FORTALEZA   (Brazil)

^u UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; HEMOGLOBIN; ISONIAZID; LAMIVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; EARLY INTERVENTION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; VASCULAR DISEASE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV-1; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84896493594     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70692-3     Document Type: Article

References (32)

1. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010, 24:123-137.
2. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. for the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC) groupsART Cohort Collaboration (ART-CC) groups.
3. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011, 154:509-515.
4. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-1826.
5. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011, 171:1560-1569. Writing Committee for the CASCADE Collaboration.
6. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363.
7. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010, 363:257-265.
8. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
9. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012, 9:e1001290.
10. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children WHO, (accessed Feb 26, 2013). http://www.who.int/hiv/pub/guidelines/hivstaging/en/index.html.
11. Schisterman EF, Cole SR, Platt RW Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009, 20:488-495.
12. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection WHO, (accessed Jan 20, 2014). http://www.who.int/hiv/pub/guidelines/arv2013/en.
13. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197:1133-1144.
14. Hughes MD, Ribaudo HR The search for data on when to start treatment for HIV infection. J Infect Dis 2008, 197:1084-1086.
15. Siegfried N, Uthman UA, Rutherford G Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev 2010, 3. CD008272.
16. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012, 54:714-723.
17. Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007, 21:1717-1721.
18. Global tuberculosis control: 2011 WHO, (accessed Jan 14, 2014). http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf.
19. Suthar AB, Lawn SD, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012, 9:e1001270.
20. Naing C, Mak JW, Maung M, Wong SF, Kassim AI Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis. Lung 2012, 191:27-34.
21. Yang Z, Kong Y, Wilson F, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004, 38:199-205.
22. Lawn SD, Zumla AI Tuberculosis. Lancet 2011, 378:57-72.
23. Chakravorty S, Sen MK, Tyagi JS Diagnosis of extrapulmonary tuberculosis by smear, culture, and PCR using universal sample processing technology. J Clin Microbiol 2005, 43:4357-4362.
24. Akolo C, Adetifa I, Shepperd S, Volmink J Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, 1. CD000171.
25. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005, 143:714-721.
26. Belloso WH, Orellana LC, Grinsztejn B, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 2010, 11:554-564.
27. Wester CW, Koethe JR, Shepherd BE, et al. Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS 2011, 25:1471-1479.
28. Batani J, Brum T, Calvet G, et al. Acceptance of ART in the delay arm after notification of interim study results: data from HPTN 052. 20th Conference on Retrovirus and Opportunistic Infections; Atlanta, GA, USA; March 3-6, 2013. 550 (poster).
29. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013, 368:218-230.
30. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
31. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012, 13(suppl 2):1-85.
32. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2012 Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and AdolescentsPanel on Antiretroviral Guidelines for Adults and Adolescents, (accessed Aug 3, 2013). http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.